BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 21635230)

  • 1. Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review.
    Pin TW; McCartney L; Lewis J; Waugh MC
    Dev Med Child Neurol; 2011 Oct; 53(10):885-95. PubMed ID: 21635230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity.
    Eek MN; Olsson K; Lindh K; Askljung B; Påhlman M; Corneliusson O; Himmelmann K
    Dev Med Child Neurol; 2018 Jan; 60(1):94-99. PubMed ID: 29148568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal baclofen therapy in non-ambulant and ambulant children and adolescents with spasticity of cerebral origin.
    Vles JS
    Dev Med Child Neurol; 2011 Nov; 53(11):1061; author reply 1062-3. PubMed ID: 22014324
    [No Abstract]   [Full Text] [Related]  

  • 4. Intrathecal baclofen for treating spasticity in children with cerebral palsy.
    Hasnat MJ; Rice JE
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD004552. PubMed ID: 26563961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive experience with intrathecal baclofen treatment in children with severe cerebral palsy.
    Overgård TM; Kjærsgaard-Hansen L; Søe M; Illum NO
    Dan Med J; 2015 Jan; 62(1):A4999. PubMed ID: 25557334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Quality of life in cerebral palsy children treated with intrathecal baclofen pump implantation in parents' opinion].
    Borowski A; Pruszczyński B; Miller F; Synder M
    Chir Narzadow Ruchu Ortop Pol; 2010; 75(5):318-22. PubMed ID: 21853903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations.
    Turner M; Nguyen HS; Cohen-Gadol AA
    J Neurosurg Pediatr; 2012 Oct; 10(4):315-9. PubMed ID: 22861196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury.
    Yoon YK; Lee KC; Cho HE; Chae M; Chang JW; Chang WS; Cho SR
    Medicine (Baltimore); 2017 Aug; 96(34):e7472. PubMed ID: 28834868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of spasticity in children and adolescents with cerebral palsy in Northern Europe: a CP-North registry study.
    Hägglund G; Hollung SJ; Ahonen M; Andersen GL; Eggertsdóttir G; Gaston MS; Jahnsen R; Jeglinsky-Kankainen I; Nordbye-Nielsen K; Tresoldi I; Alriksson-Schmidt AI
    BMC Neurol; 2021 Jul; 21(1):276. PubMed ID: 34253183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy.
    Kraus T; Gegenleitner K; Svehlik M; Novak M; Steinwender G; Singer G
    Eur J Paediatr Neurol; 2017 May; 21(3):565-569. PubMed ID: 28237420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Image-guided intrathecal baclofen pump catheter implantation: a technical note and case series.
    Robinson S; Robertson FC; Dasenbrock HH; O'Brien CP; Berde C; Padua H
    J Neurosurg Spine; 2017 May; 26(5):621-627. PubMed ID: 28156208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intrathecal baclofen on dystonia in children with cerebral palsy and the use of functional scales.
    Motta F; Stignani C; Antonello CE
    J Pediatr Orthop; 2008 Mar; 28(2):213-7. PubMed ID: 18388717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal baclofen for generalized dystonia.
    Albright AL; Barry MJ; Shafton DH; Ferson SS
    Dev Med Child Neurol; 2001 Oct; 43(10):652-7. PubMed ID: 11665821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between an Ascenda and a silicone catheter in intrathecal baclofen therapy in pediatric patients: analysis of complications.
    Motta F; Antonello CE
    J Neurosurg Pediatr; 2016 Oct; 18(4):493-498. PubMed ID: 27341610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrathecal baclofen efficacy for managing motor function and spasticity severity in patients with cerebral palsy: a systematic review and meta-analysis.
    Masrour M; Zare A; Presedo A; Nabian MH
    BMC Neurol; 2024 Apr; 24(1):143. PubMed ID: 38678195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrathecal baclofen in children with spastic cerebral palsy: a double-blind, randomized, placebo-controlled, dose-finding study.
    Hoving MA; van Raak EP; Spincemaille GH; Palmans LJ; Sleypen FA; Vles JS;
    Dev Med Child Neurol; 2007 Sep; 49(9):654-9. PubMed ID: 17718820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indwelling intrathecal catheter with subcutaneous abdominal reservoir: a viable baclofen delivery system in severely cachectic patients.
    Waqar M; Ellenbogen JR; Kumar R; Sneade C; Zebian B; Williams D; Pettorini BL
    J Neurosurg Pediatr; 2014 Oct; 14(4):409-13. PubMed ID: 25084089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter initiative to reduce intrathecal baclofen pump surgical site infection: a Cerebral Palsy Research Network quality improvement project.
    Bollo RJ; Gross PH; Rocque BG; Browd SR; Raskin JS; Leonard JR; Albarqawi L; Bailes AF;
    J Neurosurg Pediatr; 2023 May; 31(5):444-452. PubMed ID: 36840731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of botulinum toxin A in children with cerebral palsy in Gross Motor Function Classification System levels IV and V: a systematic review.
    Pin TW; Elmasry J; Lewis J
    Dev Med Child Neurol; 2013 Apr; 55(4):304-13. PubMed ID: 23095013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of continuous intrathecal baclofen therapy in children: a systematic review.
    Buizer AI; Martens BHM; Grandbois van Ravenhorst C; Schoonmade LJ; Becher JG; Vermeulen RJ
    Dev Med Child Neurol; 2019 Feb; 61(2):128-134. PubMed ID: 30187921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.